Join us for this free online event
To mark World Cancer Day 2025, our UCL panellists discuss some of the latest cancer research in their respective fields.
Book nowPioneering immunotherapy research
UCL researchers are studying new therapies for cancer and autoimmune diseases.
Here we meet some of the scientists and clinicians from the lab of Professor Hans Stauss, to find out more about their work on manipulating the body's immune system to control disease, what drives them and why they are excited about working with patients to find new cures.
Harnessing our own biology
A key strand of our approach to new cancer treatments, is to explore how we can use our own biology to our advantage - empowering immune cells, proteins and genes to recognise and eliminate cancer. Essentially using living cells, their components or products as the basis of a therapy.
New clinical trial gives hope to children with agressive blood cancer
A clinical trial for children with an aggressive type of blood cancer, led by UCL and GOSH, will run alongside an adult trial with the hope of developing more targeted and effective treatments.
New CAR T cell therapy trial shows promise for treatment of acute leukaemia
Results from the FELIX trial show how a second-generation CAR-T cell therapy, known as 'obe-cel', has reduced immune toxicity and persists for longer in patients.
Immunotherapy significantly increases number of patients free from bowel cancer
An immunotherapy drug given before surgery instead of chemotherapy meant that significantly more patients with a certain genetic profile were cancer free after surgery.
Engineering better outcomes
We look beyond the biomedicine field to leverage the strenths of our entire university - embracing a new era of engineering and computation to advance the detection, diagnosis, treatment and management of cancer.
Tumour DNA in the blood can predict lung cancer outcome
A test to detect tumour DNA circulating in the blood can predict lung cancer outcomes, finds new research from scientists at UCL, the Francis Crick Institute, UCLH and Personalis.
New screening trial to save thousands of men's lives from prostate cancer
UCL scientists will co-lead Prostate Cancer UK’s new £42m screening trial, which aims to find the best way to screen men for prostate cancer and double the number of lives saved.
Medical imaging breakthrough could transform cancer diagnosis
A new hand-held scanner developed by UCL researchers can generate highly detailed 3D photoacoustic images in just seconds, offering the potential for earlier disease diagnosis.
Leaving no one behind
One of UCL's founding principles is to achieve the greatest good for the greatest number of people. Being in the heart of London, serving a diverse population, we are determined to leave no one behind.
New precision medicine study for patients with biliary tract cancer opens
A UCL and UCLH-sponsored clinical trial aims to extend survival for some biliary tract cancer patients with treatments tailored to their tumour’s genetic profile.
New treatment for brain tumours approved following decades of work
The NHS has approved the first targeted treatment for children's brain tumours, following 20+ years of UCL research. Dabrafenib and Trametinib are 4x more effective than chemo with fewer side effects.
UCL joins £10 million project to identify individual cancer risk
The programme links data from health records, genomics, family history, and more to develop models that help scientists predict who is most likely to get cancer.
Training and supporting the next generation
UCL's is a global leader in research and education. Our scientific community is dedicated to discovering new techniques in cancer detection and treatment that can make a real difference to the lives of cancer patients.
Transforming Cancer Treatment
Breakthrough Cervical Cancer Trial
Abbie joined UCL’s INTERLACE trial after a cervical cancer diagnosis. The trial found pre-treatment with existing drugs cut death or cancer return risk by 35%, transforming global treatment. Hear from Abbie, Dr. Mary McCormack, and Simran Vaja.
Find out morePatient stories from our Cancer Trials Centre
These patients were offered CAR T-cell therapy as part of a clinical trial at UCLH when their previous treatments for lymphoma or leukaemia had proved unsuccessful.
The therapy involves collecting some of a patient’s immune cells, genetically engineering them in a lab so they are better able to target cancer, and then putting them back into the patient's body during a process called 'infusion'.
Sophie's story
Sophie, 26, began CAR T-cell therapy after her leukaemia returned for a third time. Now, things are finally getting back to normal.
Claire's story
Claire was referred to UCLH's CAR T-cell therapy trial after a difficult experience with a bone marrow transplant. She says it saved her life.
Panos's story
After three unsuccessful courses of chemotherapy, Panos underwent CAR T-cell therapy, which proved to be a 'miraculous treatment'.
